Cenra API Solutions and BioDuro Form Joint Venture to Strengthen Taiwan Based API Manufacturing for Global Markets
TAIPEI, Taiwan – 3rd March, 2026 – Cenra API Solutions(CAS), also known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB), today announced the formation of a joint venture with BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO). The joint venture will further enhance CAS/CCSB’s commercial scale active pharmaceutical ingredient (API) manufacturing platform in Taiwan and support the growing global demand for resilient and high quality supply chains.

Through this collaboration, CAS/CCSB’s established GMP manufacturing capabilities and long standing regulatory track record will be integrated with BioDuro’s strengths in early stage drug development and global client access, enabling an end to end API solution from early development through commercial scale production.

The joint venture will operate from CAS/CCSB’s Taipei campus, which currently houses 10 GMP API production lines with a total reactor volume exceeding 350,000 liters. The facility has a proven inspection history with major international regulatory agencies, including the U.S. FDA, EMA, Japan’s PMDA, and Taiwan’s TFDA.

“By combining BioDuro’s integrated CMC expertise with CAS/CCSB’s nearly six decades of GMP manufacturing excellence and enviable international regulatory history, our joint venture strengthens both companies’ global supply chain resilience and minimizes the risks of technology-transfers,” said Armin Spura, Ph.D., CEO of BioDuro. “This collaboration allows us to provide customers with truly integrated services and a drug substance solution that spans discovery chemistry, process R&D, regulatory starting materials, advanced intermediates, and clinical- to commercial-scale API production, both inside and outside mainland China, accelerating the advance of innovative therapies to market, for patients worldwide.”

“BioDuro serves more than 1,500 global customers annually with industry-leading R&D and manufacturing capabilities,” added Wayne Hsiao, President of Cenra API Solutions(CAS/CCSB). “We are excited to join forces to deliver highly integrated solutions and greater value to customers around the world.”

About Cenra API Solutions (CAS) / Chunghwa Chemical Synthesis & Biotech Co., Ltd.(CCSB)
Founded in 1964, Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) operates as Cenra API Solutions (CAS), a affiliated company of the Cenra Inc. group. CAS/CCSB was the first API manufacturer in Taiwan to receive U.S. FDA approval and focuses on the development and manufacture of high value and complex APIs, leveraging advanced biotechnology, fermentation, and chemical synthesis platforms to serve customers in more than 50 countries worldwide.
Visit the company's website: https://cenra-apisolutions.com/en/about

About BioDuro
BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive CMC capabilities, including both drug substance and drug product development.
Visit the company's website: www.BioDuro.com